Physician profile
Frampton W Henderson
NPI 1487730842
$6,232.33
in general payments reported to CMS, 2019-2025
59 companies · $1,338 in 2025
The $1,338 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $851 · 2020: $550 · 2021: $38.78 · 2022: $257 · 2023: $1,828 · 2024: $1,370 · 2025: $1,338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,522 · Education: $13.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,522.13 |
| Education | $13.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $942.00 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $505.62 | 2021-2025 | |
| Lilly USA, LLC | $453.44 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $402.88 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Sanofi-Aventis U.S. LLC | $286.62 | 2019-2024 | |
| Amgen INC. | $230.38 | 2019-2025 | Otezla, Repatha, Krystexxa |
| Sumitomo Pharma America, INC. | $223.37 | 2023-2025 | Gemtesa |
| Gilead Sciences, INC. | $169.27 | 2019-2023 | |
| Otsuka America Pharmaceutical, INC. | $167.50 | 2022-2024 | Rexulti |
| Pfizer INC. | $143.81 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.24 | 2020-2025 | Jardiance, Synjardy, Tradjenta |
| Dexcom, INC. | $135.89 | 2023-2024 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $128.67 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Exact Sciences Corporation | $124.05 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Janssen Pharmaceuticals, INC | $123.98 | 2019-2023 | Xarelto |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $110.72 | 2023-2025 | Nexletol |
| Amarin Pharma, INC. | $99.66 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $91.38 | 2020-2023 | Trintellix |
| Lundbeck LLC | $90.76 | 2023-2025 | Vyepti, Rexulti |
| Xeris Pharmaceuticals, INC. | $90.33 | 2023-2025 | Keveyis, Gvoke Hypopen, Recorlev |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $85.72 | 2025 | Caplyta |
| Axsome Therapeutics, INC. | $84.58 | 2023-2025 | Auvelity, Symbravo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.24 | 2020-2025 | Xifaxan |
| Corium, LLC | $83.16 | 2023 | Azstarys |
| Phathom Pharmaceuticals, INC. | $82.62 | 2024-2025 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $79.64 | 2024-2025 | Zoryve |
| Allergan, INC. | $79.18 | 2019-2020 | |
| Antares Pharma, INC. | $77.67 | 2020-2025 | Xyosted, Nocdurna, Tlando |
| Mylan Specialty L.P. | $63.48 | 2020-2024 | Yupelri |
| Astellas Pharma US INC | $58.87 | 2019 | |
| Boston Scientific Corporation | $54.91 | 2019-2023 | Watchman Access System |
| Merck Sharp & Dohme LLC | $54.37 | 2019-2024 | Dificid, Gardasil 9, Capvaxive |
| Kerecis Limited | $52.74 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Bayer Healthcare Pharmaceuticals INC. | $51.24 | 2023-2024 | |
| Harmony Biosciences LLC | $37.20 | 2023 | Wakix |
| Novartis Pharmaceuticals Corporation | $37.11 | 2020-2024 | |
| Horizon Therapeutics Plc | $36.66 | 2019-2023 | Krystexxa |
| Regeneron Healthcare Solutions, INC. | $35.80 | 2019-2023 | Evkeeza, Praluent |
| Axonics, INC. | $31.63 | 2022 | |
| Shire North American Group INC | $28.76 | 2019 | |
| Eisai INC. | $27.08 | 2020 | |
| Abiomed | $26.92 | 2025 | |
| Viiv Healthcare Company | $24.57 | 2025 | Apretude |
| Seqirus USA INC | $24.25 | 2025 | Flucelvax, Fluad |
| Viatris Specialty LLC | $23.76 | 2025 | Yupelri |
| Nestle Healthcare Nutrition INC. | $21.72 | 2023 | |
| Idorsia Pharmaceuticals US INC | $21.22 | 2023 | Quviviq |
| Verona Pharma, INC. | $21.19 | 2025 | Ohtuvayre |
| Vanda Pharmaceuticals INC. | $20.81 | 2025 | Fanapt, Hetlioz |
| Sanofi Pasteur INC. | $20.58 | 2023 | |
| Shield Therapeutics INC | $19.61 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $19.33 | 2024 | Eliquis |
| Paratek Pharmaceuticals, INC. | $18.41 | 2024 | Nuzyra |
| Supernus Pharmaceuticals, INC. | $17.43 | 2019 | |
| Edwards Lifesciences Corporation | $17.26 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Renalytix Ai, INC. | $15.83 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Sunovion Pharmaceuticals INC. | $12.34 | 2019 | |
| Hikma Pharmaceuticals USA | $11.58 | 2019 | |
| Sonex Health, INC. | $11.29 | 2025 | Sx-One Microknife |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frampton Henderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.